Oncobiologics Appoints Randy Thurman to Board of Directors
17 April 2018 - 3:00PM
Oncobiologics, Inc. (NASDAQ:ONS) today announced the appointment of
Randy Thurman to its board of directors, effective April 13, 2018.
At the same time, Oncobiologics also announced the resignation of
Scott Canute as director and member of the board of director’s
Nominating and Corporate Governance Committee and as Chairman of
the Compensation Committee. Mr. Thurman was also appointed to
fill Mr. Canute’s roles on such board committees.
In addition, Oncobiologics announced the
resignation of Claudio Albrecht as director and member of the board
of director’s Nominating and Corporate Governance Committee. Mr.
Yezan Haddadin was nominated by GMS Tenshi Holdings Pte. Limited to
rejoin the board and fill the vacancy created by Mr. Albrecht’s
departure. In connection, the board appointed Mr. Haddadin to fill
the vacancy on the board, and to replace Mr. Albrecht as a member
of the board of director’s Nominating and Corporate Governance
Committee.
“I’m very pleased that Mr. Randy Thurman is
joining our board of directors,” said Oncobiologics’ Chairman &
CEO Dr. Pankaj Mohan. “Randy is an experienced and well respected
life sciences industry executive and public company director with a
track record of building businesses and creating shareholder value
through product development, strategic marketing and M&A. His
broad expertise in building successful companies will be a great
benefit to us.”
Mr. Thurman is currently a senior advisor at BC
Partners, a private equity firm, and is also currently a member of
the Board of Directors at Allscripts, Inc. and Zest Dental, Inc. In
the span of his career, Mr. Thurman has previously been the
President of both Rorer and Rhone-Polenc Rorer Pharmaceuticals, CEO
of Corning Life Sciences, and Chairman and CEO of VIASYS
Healthcare, Inc., as well as a member of the board for over 15
public and private companies.
“While we are excited to add Randy Thurman to
our board, we are sad to see Scott Canute and Claudio Albrecht
leaving,” Dr. Mohan continued. “Scott has been a supporter
and a member of our board for many years and he will be
missed. It is unfortunate that both Scott and Claudio were
beset with too many demands on their time to continue on our
board. However, I am happy to see that Yezan Haddadin has
been selected to rejoin the board as one of the GMS Tenshi
designees.”
About Oncobiologics, Inc. and its
BioSymphony™ Platform
Oncobiologics is a clinical-stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex biosimilar therapeutics.
Its current focus is on technically challenging and commercially
attractive monoclonal antibodies (mAbs) in the disease areas of
immunology and oncology. Oncobiologics is advancing its pipeline of
biosimilar products, two of which are currently in clinical
development. Led by a team of biopharmaceutical experts,
Oncobiologics operates from an in-house state-of-the-art fully
integrated research and development, and manufacturing facility in
Cranbury, New Jersey. Oncobiologics employs its BioSymphony™
Platform to address the challenges of biosimilar development and
commercialization by developing high quality mAb biosimilars in an
efficient and cost-effective manner on an accelerated timeline. For
more information, please visit www.oncobiologics.com.
CONTACTS:
Oncobiologics: |
Lawrence A.
KenyonChief Financial OfficerLawrenceKenyon@oncobiologics.com |
|
|
Media &
Investors: |
Alex FudukidisRusso
Partners, LLCalex.fudukidis@russopartnersllc.com |
Oncobiologics Series A Warrant Expiring 2/18/2019 (delisted) (NASDAQ:ONSIW)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Oncobiologics Series A Warrant Expiring 2/18/2019 (delisted) (NASDAQ:ONSIW)
Historical Stock Chart
Von Nov 2023 bis Nov 2024